Evidence map›Paper›PMID 41023889›Full record

ArticleBMC infectious diseases2025

Assessment of direct-acting antiviral treatment outcomes in patients with chronic hepatitis C infected with various HCV genotypes: Insights from a real-world cohort in West Bengal, India.

Supradip Dutta, Shreyasi Nath, Raina Das, Sagnik Bakshi, Moumita Majumdar, Anwesha Ghosh, Upasana Baskey, Prosanto Kumar Chowdhury, Provash Chandra Sadhukhan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Supradip Dutta *Indian Council of Medical Research-National Institute for Research in Bacterial Infections (formerly Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases), P-33, Scheme XM, CIT Road, Beliaghata, Kolkata, West Bengal, 700010, India.
Shreyasi Nath *Indian Council of Medical Research-National Institute for Research in Bacterial Infections (formerly Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases), P-33, Scheme XM, CIT Road, Beliaghata, Kolkata, West Bengal, 700010, India.
Raina DasIndian Council of Medical Research-National Institute for Research in Bacterial Infections (formerly Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases), P-33, Scheme XM, CIT Road, Beliaghata, Kolkata, West Bengal, 700010, India.
Sagnik BakshiIndian Council of Medical Research-National Institute for Research in Bacterial Infections (formerly Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases), P-33, Scheme XM, CIT Road, Beliaghata, Kolkata, West Bengal, 700010, India.
Moumita MajumdarIndian Council of Medical Research-National Institute for Research in Bacterial Infections (formerly Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases), P-33, Scheme XM, CIT Road, Beliaghata, Kolkata, West Bengal, 700010, India.
Anwesha GhoshIndian Council of Medical Research-National Institute for Research in Bacterial Infections (formerly Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases), P-33, Scheme XM, CIT Road, Beliaghata, Kolkata, West Bengal, 700010, India.
Upasana BaskeyIndian Council of Medical Research-National Institute for Research in Bacterial Infections (formerly Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases), P-33, Scheme XM, CIT Road, Beliaghata, Kolkata, West Bengal, 700010, India.
Prosanto Kumar ChowdhuryPeerless Hospital & B. K. Roy Research Centre, 360 Panchasayar, Kolkata, 700094, India.
Provash Chandra SadhukhanIndian Council of Medical Research-National Institute for Research in Bacterial Infections (formerly Indian Council of Medical Research-National Institute of Cholera and Enteric Diseases), P-33, Scheme XM, CIT Road, Beliaghata, Kolkata, West Bengal, 700010, India. provash2000@gmail.com.ORCID http://orcid.org/0000-0002-7014-0530

Funding

Department of Science and Technology, Govt. of West Bengal 758(sanc.)/ST/P/S&T/9G-8/2014, dated-27.11.2014
6 · The paper itself

Abstract

BACKGROUND &

objectivesGenomic diversity of Hepatitis C Virus (HCV), accessibility and long-term influence of Direct Acting Antiviral (DAA) treatment remain underexplored among HCV-infected chronic liver disease (CLD) patients in the real world. This retrospective study addressed the inadequacy of assessing the effectiveness of DAA and identify genotype-specific variations in treatment response in the context of HCV epidemiology. Additionally, real-world treatment challenges encountered during the COVID-19 pandemic and the transitional phase of implementing the National Viral Hepatitis Control Program (NVHCP) guidelines have also been addressed.

methodsThis retrospective study included 254 CLD patients from November 2017 and February 2020 to assess the effectiveness of DAA and long-term treatment outcomes among CLD patients.

resultsHCV viremia was observed in 58.26% (n = 148) patients. Patients aged 52-59 years with a history of blood transfusions exhibited a higher prevalence of active HCV infection. Two major genotypes (GT) - GT1 and GT3, and seven subtypes with few new subtypes were identified. SVR INTERPRETATION &

conclusionThis study highlights genotype-specific variations in treatment response, with GT-3b exhibiting lower treatment response which highlights the need to decipher the reasons behind treatment failure for future therapeutic management.

Indexed as

Antiviral AgentsHepacivirusHepatitis C, ChronicAdultAgedCarbamatesCOVID-19Drug Therapy, CombinationFemaleGenotypeHumansImidazolesIndiaMaleMiddle AgedPyrrolidinesAntiviral AgentsCarbamatesdaclatasvirImidazolesPyrrolidinesSofosbuvirValineChronic liver diseaseDirect acting antiviralsFollow-up studyGenotype distributionHepatitis c virusRetrospective studyTreatment outcome

Identifiers

PMID41023889
PMCPMC12481875

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.